Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States.

ABSTRACT:

Importance

The antifungal medication voriconazole is used to prevent and treat aspergillosis, a major cause of mortality among recipients of lung transplants (hereinafter referred to as lung recipients). Small studies suggest that voriconazole increases risk of cutaneous squamous cell carcinoma (SCC).

Objective

To examine associations of voriconazole and other antifungal medications with risk of keratinocyte carcinomas (SCC and cutaneous basal cell carcinoma [BCC]) in lung recipients.

Design, setting, and participants

This population-based cohort study included non-Hispanic white patients (n = 9599) who underwent lung transplant in the United States from January 1, 2007, to December 31, 2016, identified through the national Scientific Registry of Transplant Recipients

SUBMITTER: D'Arcy ME 

PROVIDER: S-EPMC7221851 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature